Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELVET trial of subcutaneous veltuzumab in rheumatoid arthritis
2010-022378-15Phase 2Terminated
- Sponsor
- Nycomed
- Start
- Feb 2011
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of veltuzumab in rheumatoid arthritis (RA) (4 arms), sponsored by Nycomed. Primary endpoint: ACR20 responder rate at week 24. Started Feb 2011; status: terminated.
02
Drugs
veltuzumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-022378-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022378-15.